Salibian Arthur H, Harness Jay K, Mowlds Donald S
Orange, Calif.
From St. Joseph Hospital and the Departments of Plastic Surgery and Surgery, University of California Irvine Medical Center.
Plast Reconstr Surg. 2017 Jan;139(1):30-39. doi: 10.1097/PRS.0000000000002845.
Since the introduction of nipple-sparing mastectomy as an oncologically safe procedure for the treatment of breast cancer, reconstructive efforts for immediate staged expander/implant reconstruction have focused on submuscular implantation with or without acellular dermal matrix. Suprapectoral reconstruction without acellular dermal matrix has received little attention in the reconstructive literature of nipple-sparing mastectomy.
Between 2005 and 2015, 155 patients (250 breasts) underwent nipple-sparing mastectomy with prepectoral staged expander/implant reconstruction using thick mastectomy skin flaps without acellular dermal matrix. Patients with different breast sizes, including those patients with very large breasts who required a primary mastopexy, were considered candidates for the suprapectoral reconstruction. Tumor-related data, comorbidities, and preoperative or postoperative radiation therapy were evaluated for correlation with the final outcome.
Patients were followed up for an average of 55.5 months (range, 138.1 to 23.6 months). The tumor recurrence rate was 2.6 percent. Adverse outcomes such as capsular contracture, implant dystopia, and rippling were studied. Aesthetic outcome, based on a three-point evaluation scale, showed 53.6 percent of patients as having a very good result, 31.6 percent showing a good result, 9 percent showing a fair result, and 5.8 percent showing a poor result.
The suprapectoral two-stage expander/implant reconstruction without acellular dermal matrix in nipple-sparing mastectomy has certain advantages with respect to breast shape, less morbidity related to expansion, ease of reconstruction, and cost effectiveness. These advantages have to be weighed against those of subpectoral reconstruction with acellular dermal matrix to determine the method of choice.
CLINCAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
自从保留乳头的乳房切除术作为一种治疗乳腺癌的肿瘤学安全手术被引入以来,即刻分期扩张器/植入物重建的重建方法一直集中在使用或不使用脱细胞真皮基质的胸肌下植入。在保留乳头的乳房切除术后重建文献中,不使用脱细胞真皮基质的胸肌上重建很少受到关注。
2005年至2015年期间,155例患者(250侧乳房)接受了保留乳头的乳房切除术,并采用不使用脱细胞真皮基质的厚乳房切除皮瓣进行胸肌前分期扩张器/植入物重建。不同乳房大小的患者,包括那些需要一期乳房上提术的非常大乳房的患者,均被视为胸肌上重建的候选者。评估肿瘤相关数据、合并症以及术前或术后放疗与最终结果的相关性。
患者平均随访55.5个月(范围为23.6至138.1个月)。肿瘤复发率为2.6%。研究了诸如包膜挛缩、植入物异位和波纹等不良后果。基于三分评估量表的美学结果显示,53.6%的患者结果非常好,31.6%的患者结果良好,9%的患者结果尚可,5.8%的患者结果较差。
在保留乳头的乳房切除术中,不使用脱细胞真皮基质的胸肌上两阶段扩张器/植入物重建在乳房形状、与扩张相关的发病率较低、重建容易以及成本效益方面具有一定优势。必须将这些优势与使用脱细胞真皮基质的胸肌下重建的优势进行权衡,以确定选择的方法。
临床问题/证据水平:治疗性,IV级。